Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Infectious Disease Reports
Published in: Current Infectious Disease Reports 10/2023

02-09-2023 | Mpox Virus | Tropical, Travel and Emerging Infections (LH Chen and F Norman, Section Editors)

Mpox in 2023: Current Epidemiology and Management

Authors: Sapha Barkati, Luke B. Harrison, Marina B. Klein, Francesca F. Norman

Published in: Current Infectious Disease Reports | Issue 10/2023

Login to get access

Abstract

Purpose of Review

The 2022 global mpox outbreak is a significant public health challenge. This review provides a summary of recent advancements in mpox phylogenetics, epidemiology, transmission, clinical presentation, treatment, and vaccination.

Recent Findings

The 2022 outbreak saw a shift in epidemiology, with human-to-human transmission, particularly among men who have sex with men (MSM), becoming the primary mode of spread. Among IIb.B.1 sequences, there is evidence for an emerging human-adapted monkeypox virus (MPXV). Antiviral treatments like tecovirimat have shown promise in severe cases. Two doses of the non-replicative 3rd generation vaccine MVA-BN provide better protection than a single dose.

Summary

This outbreak underscores the importance of global surveillance, prompt response, and effective vaccination strategies in managing emerging infectious diseases. Efforts to destigmatize the disease and increase awareness among high-risk populations are vital in curbing transmission. Continued research and international collaboration are essential for understanding the MPXV and improving preparedness for future outbreaks.
Literature
1.
Von Magnus PAEK, Petersen KB, Birch-Andersen A. A pox-like disease in cynomolgus monkeys. Acta Pathol Microbiol Scand. 1959;46(2):156–76.CrossRef
2.
Ladnyj ID, Ziegler P, Kima E. A human infection caused by monkeypox virus in Basankusu Territory, Democratic Republic of the Congo. Bull World Health Organ. 1972;46(5):593–7.PubMedPubMedCentral
3.
Breman JG, Kalisa R, Steniowski MV, Zanotto E, Gromyko AI, Arita I. Human monkeypox, 1970–79. Bull World Health Organ. 1980;58(2):165–82.PubMedPubMedCentral
4.
Fine PE, Jezek Z, Grab B, Dixon H. The transmission potential of monkeypox virus in human populations. Int J Epidemiol. 1988;17(3):643–50.PubMedCrossRef
5.
Centers for Disease C, Prevention. Update: multistate outbreak of monkeypox--Illinois, Indiana, Kansas, Missouri, Ohio, and Wisconsin, 2003. MMWR Morb Mortal Wkly Rep. 2003;52(27):642–6.
6.
Rimoin AW, Mulembakani PM, Johnston SC, Lloyd Smith JO, Kisalu NK, Kinkela TL, et al. Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo. Proc Natl Acad Sci USA. 2010;107(37):16262–7.PubMedPubMedCentralCrossRef
7.
Alakunle E, Moens U, Nchinda G, Okeke MI. Monkeypox virus in Nigeria: infection biology, epidemiology, and evolution. Viruses. 2020;12(11).
8.
Yinka-Ogunleye A, Aruna O, Ogoina D, Aworabhi N, Eteng W, Badaru S, et al. Reemergence of human monkeypox in Nigeria, 2017. Emerg Infect Dis. 2018;24(6):1149–51.PubMedPubMedCentralCrossRef
9.
Vaughan A, Aarons E, Astbury J, Balasegaram S, Beadsworth M, Beck CR, et al. Two cases of monkeypox imported to the United Kingdom, September 2018. Euro Surveill. 2018;23(38).
10.
Erez N, Achdout H, Milrot E, Schwartz Y, Wiener-Well Y, Paran N, et al. Diagnosis of imported monkeypox, Israel, 2018. Emerg Infect Dis. 2019;25(5):980–3.PubMedPubMedCentralCrossRef
11.
Angelo KM, Petersen BW, Hamer DH, Schwartz E, Brunette G. Monkeypox transmission among international travellers-serious monkey business? J Travel Med. 2019;26(5).
12.
13.
14.
Vaughan A, Aarons E, Astbury J, Brooks T, Chand M, Flegg P, et al. Human-to-human transmission of monkeypox virus, United Kingdom, October 2018. Emerg Infect Dis. 2020;26(4):782–5.PubMedPubMedCentralCrossRef
15.
Hobson G, Adamson J, Adler H, Firth R, Gould S, Houlihan C, et al. Family cluster of three cases of monkeypox imported from Nigeria to the United Kingdom, May 2021. Euro Surveill. 2021;26(32).
16.
17.
Vivancos R, Anderson C, Blomquist P, Balasegaram S, Bell A, Bishop L, et al. Community transmission of monkeypox in the United Kingdom, April to May 2022. Euro Surveill. 2022;27(22).
18.
19.
20.
Perez Duque M, Ribeiro S, Martins JV, Casaca P, Leite PP, Tavares M, et al. Ongoing monkeypox virus outbreak, Portugal, 29 April to 23 May 2022. Euro Surveill. 2022;27(22).
21.
Inigo Martinez J, Gil Montalban E, Jimenez Bueno S, Martin Martinez F, Nieto Julia A, Sanchez Diaz J, et al. Monkeypox outbreak predominantly affecting men who have sex with men, Madrid, Spain, 26 April to 16 June 2022. Euro Surveill. 2022;27(27).
22.
Selb R, Werber D, Falkenhorst G, Steffen G, Lachmann R, Ruscher C, et al. A shift from travel-associated cases to autochthonous transmission with Berlin as epicentre of the monkeypox outbreak in Germany, May to June 2022. Euro Surveill. 2022;27(27).
23.
24.
•• Thornhill JP, Barkati S, Walmsley S, Rockstroh J, Antinori A, Harrison LB, et al. Monkeypox virus infection in humans across 16 countries - April-June 2022. N Engl J Med. 2022;387(8):679–91. This is the largest international case series published on epidemiology, clinical presentation, clinical course, and outcome of mpox early in the pandemic. It also includes an extensive image library illustrating the evolution of the lesions, showcasing various type and locations (cutaneous, genital, mucosal).
25.
• Angelo KM, Smith T, Camprubi-Ferrer D, Balerdi-Sarasola L, Diaz Menendez M, Servera-Negre G, et al. Epidemiological and clinical characteristics of patients with monkeypox in the GeoSentinel Network: a cross-sectional study. Lancet Infect Dis. 2023;23(2):196–206. In this study, surveillance data available from the GeoSentinel Network, which were the first clinical sites to identify mpox cases in the current epidemic, were used to investigate the epidemiological and clinical characteristics and outcomes of patients with mpox.
26.
Tarin-Vicente EJ, Alemany A, Agud-Dios M, Ubals M, Suner C, Anton A, et al. Clinical presentation and virological assessment of confirmed human monkeypox virus cases in Spain: a prospective observational cohort study. Lancet. 2022;400(10353):661–9.PubMedPubMedCentralCrossRef
27.
Patel A, Bilinska J, Tam JCH, Da Silva FD, Mason CY, Daunt A, et al. Clinical features and novel presentations of human monkeypox in a Central London centre during the 2022 outbreak: descriptive case series. BMJ. 2022;378:e072410.PubMedPubMedCentralCrossRef
28.
•• Mitja O, Alemany A, Marks M, Lezama Mora JI, Rodriguez-Aldama JC, Torres Silva MS, et al. Mpox in people with advanced HIV infection: a global case series. Lancet. 2023;401(10380):939–49. In the context of HIV with advanced immunosuppression (CD4 counts below 200 cells per mm3), this study revealed the emergence of a severe necrotising type of mpox, characterized by notable systemic manifestations and fatal outcomes.
29.
•• Thornhill JP, Palich R, Ghosn J, Walmsley S, Moschese D, Cortes CP, et al. Human monkeypox virus infection in women and non-binary individuals during the 2022 outbreaks: a global case series. Lancet. 2022;400(10367):1953–65. In this international case series, comprising 62 trans women, 69 cis women, and five non-binary individuals who were diagnosed with mpox from May 2022 onwards, a comprehensive exploration of the epidemiological, clinical, and diagnostic aspects, as well as complications, is presented within these lesser-studied populations.
30.
•• Nemechek K, Stefanos R, Miller EL, Riser A, Kebede B, Galang RR, et al. Notes from the field: exposures to mpox among cases in children aged </=12 years - United States, September 25-December 31, 2022. MMWR Morb Mortal Wkly Rep. 2023;72(23):633–5. During the 2022 mpox outbreak, infection in children was rare. This collection of cases offers valuable insights into how children were exposed to mpox, highlighting the notable role of household contact as a key mode of transmission.
31.
32.
• Harrison LB, Bergeron G, Cadieux G, Charest H, Fafard J, Levade I, et al. Monkeypox in Montreal: epidemiology, phylogenomics, and public health response to a large North American outbreak. Ann Intern Med. 2023;176(1):67–76. This study characterize the first large mpox outbreak in North America and demonstrated the importance of early and sustained engagement with the affected communities as well as public health measures including the rapid offer of preexposure vaccination to effectively manage the outbreak.
33.
• van Ewijk CE, Miura F, van Rijckevorsel G, de Vries HJ, Welkers MR, van den Berg OE, et al. Mpox outbreak in the Netherlands, 2022: public health response, characteristics of the first 1,000 cases and protection of the first-generation smallpox vaccine. Euro Surveill. 2023;28(12). This study describes characteristics of the first 1,000 mpox cases in the Netherlands, reported between 20 May and 8 August 2022, within the context of the public health response. In addition, protective effect of the first-generation smallpox vaccine was estimated against moderate to severe disease revealing a moderate level of protection.
34.
Vanhamel J, Laisnez V, Liesenborghs L, Brosius I, Berens-Riha N, Vanbaelen T, et al. Understanding sexual transmission dynamics and transmission contexts of monkeypox virus: a mixed-methods study of the early outbreak in Belgium (May-June 2022). Sex Transm Infect. 2022.
35.
• Van Dijck C, Hens N, Kenyon C, Tsoumanis A. The roles of unrecognized mpox cases, contact isolation and vaccination in determining epidemic size in Belgium: a modeling study. Clin Infect Dis. 2023;76(3):e1421–e3. The findings of this study suggest that undetected infections play a significant role in shaping the epidemic’s impact. Furthermore, vaccinating individuals who are most susceptible to infection appears to have a greater impact on diminishing the overall size of the epidemic compared to administering vaccinations to sexual partners after exposure.
36.
Vairo F, Leone S, Mazzotta V, Piselli P, De Carli G, Lanini S, et al. The possible effect of sociobehavioral factors and public health actions on the mpox epidemic slowdown. Int J Infect Dis. 2023;130:83–5.PubMedCrossRef
37.
38.
39.
Likos AM, Sammons SA, Olson VA, Frace AM, Li Y, Olsen-Rasmussen M, et al. A tale of two clades: monkeypox viruses. J Gen Virol. 2005;86(Pt 10):2661–72.PubMedCrossRef
40.
Nakazawa Y, Mauldin MR, Emerson GL, Reynolds MG, Lash RR, Gao J, et al. A phylogeographic investigation of African monkeypox. Viruses. 2015;7(4):2168–84.PubMedPubMedCentralCrossRef
41.
Hutson CL, Carroll DS, Gallardo-Romero N, Drew C, Zaki SR, Nagy T, et al. Comparison of monkeypox virus clade kinetics and pathology within the prairie dog animal model using a serial sacrifice study design. Biomed Res Int. 2015;2015: 965710.PubMedPubMedCentralCrossRef
42.
Americo JL, Earl PL, Moss B. Virulence differences of mpox (monkeypox) virus clades I, IIa, and IIb.1 in a small animal model. Proc Natl Acad Sci USA. 2023;120(8):e2220415120.
43.
•• Happi C, Adetifa I, Mbala P, Njouom R, Nakoune E, Happi A, et al. Urgent need for a non-discriminatory and non-stigmatizing nomenclature for monkeypox virus. PLoS Biol. 2022;20(8):e3001769. This article porpose a non-discriminatory, non-stigmatizing, and neutral classification of monkeypox virus diversity, aligned with best practices in naming of infectious diseases.
44.
Antinori A, Mazzotta V, Vita S, Carletti F, Tacconi D, Lapini LE, et al. Epidemiological, clinical and virological characteristics of four cases of monkeypox support transmission through sexual contact, Italy, May 2022. Euro Surveill. 2022;27(22).
45.
46.
Ulaeto D, Agafonov A, Burchfield J, Carter L, Happi C, Jakob R, et al. New nomenclature for mpox (monkeypox) and monkeypox virus clades. Lancet Infect Dis. 2023;23(3):273–5.PubMedPubMedCentralCrossRef
47.
Gigante CM, Korber B, Seabolt MH, Wilkins K, Davidson W, Rao AK, et al. Multiple lineages of monkeypox virus detected in the United States, 2021–2022. Science. 2022;378(6619):560–5.PubMedPubMedCentralCrossRef
48.
Jolly B, Scaria V. A distinct phylogenetic cluster of monkeypox genomes suggests an early and cryptic spread of the virus. J Infect. 2023;86(1):e24–6.PubMedCrossRef
49.
50.
Isidro J, Borges V, Pinto M, Sobral D, Santos JD, Nunes A, et al. Phylogenomic characterization and signs of microevolution in the 2022 multi-country outbreak of monkeypox virus. Nat Med. 2022;28(8):1569–72.PubMedPubMedCentralCrossRef
51.
Luna N, Munoz M, Bonilla-Aldana DK, Patino LH, Kasminskaya Y, Paniz-Mondolfi A, et al. Monkeypox virus (MPXV) genomics: a mutational and phylogenomic analyses of B.1 lineages. Travel Med Infect Dis. 2023;52:102551.
52.
Reed KD, Melski JW, Graham MB, Regnery RL, Sotir MJ, Wegner MV, et al. The detection of monkeypox in humans in the Western Hemisphere. N Engl J Med. 2004;350(4):342–50.PubMedCrossRef
53.
Reynolds MG, Yorita KL, Kuehnert MJ, Davidson WB, Huhn GD, Holman RC, et al. Clinical manifestations of human monkeypox influenced by route of infection. J Infect Dis. 2006;194(6):773–80.PubMedCrossRef
54.
Allan-Blitz LT, Gandhi M, Adamson P, Park I, Bolan G, Klausner JD. A position statement on mpox as a sexually transmitted disease. Clin Infect Dis. 2023;76(8):1508–12.PubMedCrossRef
55.
Lapa D, Carletti F, Mazzotta V, Matusali G, Pinnetti C, Meschi S, et al. Monkeypox virus isolation from a semen sample collected in the early phase of infection in a patient with prolonged seminal viral shedding. Lancet Infect Dis. 2022;22(9):1267–9.PubMedPubMedCentralCrossRef
56.
• Palich R, Burrel S, Monsel G, Nouchi A, Bleibtreu A, Seang S, et al. Viral loads in clinical samples of men with monkeypox virus infection: a French case series. Lancet Infect Dis. 2023;23(1):74–80. The study showed higher MPXV detection in skin, anus, and throat samples compared to blood, urine, and semen, with elevated viral loads in skin and mucosa samples, suggesting direct body contact as the likely mode of transmission.
57.
Beeson A, Styczynski A, Hutson CL, Whitehill F, Angelo KM, Minhaj FS, et al. Mpox respiratory transmission: the state of the evidence. Lancet Microbe. 2023;4(4):e277–83.PubMedPubMedCentralCrossRef
58.
Hazra A, Cherabie JN. Is mpox a sexually transmitted infection? Why narrowing the scope of this disease may be harmful. Clin Infect Dis. 2023;76(8):1504–7.PubMedCrossRef
59.
De Baetselier I, Van Dijck C, Kenyon C, Coppens J, Michiels J, de Block T, et al. Retrospective detection of asymptomatic monkeypox virus infections among male sexual health clinic attendees in Belgium. Nat Med. 2022;28(11):2288–92.PubMedPubMedCentralCrossRef
60.
Ferre VM, Bachelard A, Zaidi M, Armand-Lefevre L, Descamps D, Charpentier C, et al. Detection of monkeypox virus in anorectal swabs from asymptomatic men who have sex with men in a sexually transmitted infection screening program in Paris, France. Ann Intern Med. 2022;175(10):1491–2.PubMedCrossRef
61.
Satapathy P, Mohanty P, Manna S, Shamim MA, Rao PP, Aggarwal AK, et al. Potentially asymptomatic infection of monkeypox virus: a systematic review and meta-analysis. Vaccines (Basel). 2022;10(12).
62.
Rossotti R, Calzavara D, Cernuschi M, D'Amico F, De Bona A, Repossi R, et al. Detection of asymptomatic mpox carriers among high-risk men who have sex with men: a prospective analysis. Pathogens. 2023;12(6).
63.
Van Dijck C, De Baetselier I, Kenyon C, Liesenborghs L, Group ITMMS, Vercauteren K, et al. Mpox screening in high-risk populations finds no asymptomatic cases. Lancet Microbe. 2023;4(3):e132–e3.
64.
• Ward T, Christie R, Paton RS, Cumming F, Overton CE. Transmission dynamics of monkeypox in the United Kingdom: contact tracing study. BMJ. 2022;379:e073153. This study utilized contact tracing data and identified evidence of pre-symptomatic transmission, with the maximum time of transmission detected before symptoms appeared being 4 days.
65.
Zachary KC, Philpotts LL, Shenoy ES. Mpox exposure and transmission in healthcare settings during the 2022 global outbreak. Curr Opin Infect Dis. 2023;36(4):257–62.PubMedCrossRef
66.
67.
Viedma-Martinez M, Dominguez-Tosso FR, Jimenez-Gallo D, Garcia-Palacios J, Riera-Tur L, Montiel-Quezel N, et al. MPXV transmission at a tattoo parlor. N Engl J Med. 2023;388(1):92–4.PubMedCrossRef
68.
Del Rio GV, Palacios JG, Morcillo AM, Duran-Pla E, Rodriguez BS, Lorusso N. Monkeypox outbreak in a piercing and tattoo establishment in Spain. Lancet Infect Dis. 2022;22(11):1526–8.CrossRef
69.
Beaumont AL, Raphael E, Bertin C, Lariven S, Peiffer-Smadja N. Mpox lesions on a tattoo. Lancet Infect Dis. 2023;23(6):762.PubMedCrossRef
70.
71.
Mbala PK, Huggins JW, Riu-Rovira T, Ahuka SM, Mulembakani P, Rimoin AW, et al. Maternal and fetal outcomes among pregnant women with human monkeypox infection in the democratic Republic of Congo. J Infect Dis. 2017;216(7):824–8.PubMedCrossRef
72.
Ramnarayan P, Mitting R, Whittaker E, Marcolin M, O’Regan C, Sinha R, et al. Neonatal monkeypox virus infection. N Engl J Med. 2022;387(17):1618–20.PubMedCrossRef
73.
Alonso-Cadenas JA, Andina-Martinez D, Garcia-Garcia CJ, Gaitero-Tristan J, Garcia-Ascaso MT, Torrelo A. Monkeypox disease in a breastfeeding infant. Pediatr Dermatol. 2023;40(1):214–5.PubMedCrossRef
74.
Hennessee I, Shelus V, McArdle CE, Wolf M, Schatzman S, Carpenter A, et al. Epidemiologic and clinical features of children and adolescents aged <18 years with monkeypox - United States, May 17-September 24, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(44):1407–11.PubMedPubMedCentralCrossRef
75.
Pinto P, Costa MA, Goncalves MFM, Rodrigues AG, Lisboa C. Mpox person-to-person transmission-where have we got so far? A systematic review. Viruses. 2023;15(5).
76.
Pfeiffer JA, Collingwood A, Rider LE, Minhaj FS, Matheny AM, Kling C, et al. High-contact object and surface contamination in a household of persons with monkeypox virus infection - Utah, June 2022. MMWR Morb Mortal Wkly Rep. 2022;71(34):1092–4.PubMedPubMedCentralCrossRef
77.
Morgan CN, Whitehill F, Doty JB, Schulte J, Matheny A, Stringer J, et al. Environmental persistence of monkeypox virus on surfaces in household of person with travel-associated infection, Dallas, Texas, USA, 2021. Emerg Infect Dis. 2022;28(10):1982–9.PubMedPubMedCentralCrossRef
78.
•• Rao AK, Schrodt CA, Minhaj FS, Waltenburg MA, Cash-Goldwasser S, Yu Y, et al. Interim clinical treatment considerations for severe manifestations of mpox - United States, February 2023. MMWR Morb Mortal Wkly Rep. 2023;72(9):232–43. In this article, data relevant to the use of antiviral treatments and vaccinia immune globulin intravenous are reviewed. An approach to treatment of patient with severe or at risk for severe manifestation of mpox is provided.
79.
Shamim MA, Padhi BK, Satapathy P, Veeramachaneni SD, Chatterjee C, Tripathy S, et al. The use of antivirals in the treatment of human monkeypox outbreaks: a systematic review. Int J Infect Dis. 2023;127:150–61.PubMedCrossRef
80.
Oakley LP, Hufstetler K, O’Shea J, Sharpe JD, McArdle C, Neelam V, et al. Mpox cases among cisgender women and pregnant persons - United States, May 11-November 7, 2022. MMWR Morb Mortal Wkly Rep. 2023;72(1):9–14.PubMedPubMedCentralCrossRef
81.
82.
Quenelle DC, Prichard MN, Keith KA, Hruby DE, Jordan R, Painter GR, et al. Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses. Antimicrob Agents Chemother. 2007;51(11):4118–24.PubMedPubMedCentralCrossRef
83.
Sobral-Costas TG, Escudero-Tornero R, Servera-Negre G, Bernardino JI, Arroyo AG, Diaz-Menendez M, et al. Human monkeypox outbreak: epidemiological data and therapeutic potential of topical cidofovir in a prospective cohort study. J Am Acad Dermatol. 2022.
84.
Bojkova D, Zoller N, Tietgen M, Steinhorst K, Bechtel M, Rothenburger T, et al. Repurposing of the antibiotic nitroxoline for the treatment of mpox. J Med Virol. 2023.
85.
Akazawa D, Ohashi H, Hishiki T, Morita T, Iwanami S, Kim KS, et al. Potential anti-mpox virus activity of atovaquone, mefloquine, and molnupiravir, and their potential use as treatments. J Infect Dis. 2023.
86.
87.
•• Deputy NP, Deckert J, Chard AN, Sandberg N, Moulia DL, Barkley E, et al. Vaccine effectiveness of JYNNEOS against mpox disease in the United States. N Engl J Med. 2023;388(26):2434–43. Using the nationwide Epic electronic health record database Cosmos, this case-control study found that the JYNNEOS vaccine was effective in preventing mpox disease in adults, particularly with a two-dose series.
88.
Wolff Sagy Y, Zucker R, Hammerman A, Markovits H, Arieh NG, Abu Ahmad W, et al. Real-world effectiveness of a single dose of mpox vaccine in males. Nat Med. 2023;29(3):748–52.PubMedPubMedCentralCrossRef
89.
Bertran M, Andrews N, Davison C, Dugbazah B, Boateng J, Lunt R, et al. Effectiveness of one dose of MVA-BN smallpox vaccine against mpox in England using the case-coverage method: an observational study. Lancet Infect Dis. 2023;23(7):828–35.PubMedCrossRef
90.
91.
Montero Morales L, Barbas Del Buey JF, Alonso Garcia M, Cenamor Largo N, Nieto Julia A, Vazquez Torres MC, et al. Post-exposure vaccine effectiveness and contact management in the mpox outbreak, Madrid, Spain, May to August 2022. Euro Surveill. 2023;28(24).
92.
Rosenberg ES, Dorabawila V, Hart-Malloy R, Anderson BJ, Miranda W, O’Donnell T, et al. Effectiveness of JYNNEOS vaccine against diagnosed mpox infection - New York, 2022. MMWR Morb Mortal Wkly Rep. 2023;72(20):559–63.PubMedPubMedCentralCrossRef
93.
• Zaeck LM, Lamers MM, Verstrepen BE, Bestebroer TM, van Royen ME, Gotz H, et al. Low levels of monkeypox virus-neutralizing antibodies after MVA-BN vaccination in healthy individuals. Nat Med. 2023;29(1):270–8. The study indicates that those with prior mpox infection or first-generation smallpox vaccine have neutralizing antibodies against mpox. Yet, two doses of MVA-BN vaccine in individuals with no prior exposure yield relatively low levels of MPXV-neutralizing antibodies.
94.
Hubert M, Guivel-Benhassine F, Bruel T, Porrot F, Planas D, Vanhomwegen J, et al. Complement-dependent mpox-virus-neutralizing antibodies in infected and vaccinated individuals. Cell Host Microbe. 2023;31(6):937–48 e4.
95.
Golden J, Harryman L, Crofts M, Muir P, Donati M, Gillett S, et al. Case of apparent mpox reinfection. Sex Transm Infect. 2023;99(4):283–4.PubMedCrossRef
96.
97.
Ladhani SN, Dowell AC, Jones S, Hicks B, Rowe C, Begum J, et al. Early evaluation of the safety, reactogenicity, and immune response after a single dose of modified vaccinia Ankara-Bavaria Nordic vaccine against mpox in children: a national outbreak response. Lancet Infect Dis. 2023.
Metadata
Title
Mpox in 2023: Current Epidemiology and Management
Authors
Sapha Barkati
Luke B. Harrison
Marina B. Klein
Francesca F. Norman
Publication date
02-09-2023
Publisher
Springer US
Published in
Current Infectious Disease Reports / Issue 10/2023
Print ISSN: 1523-3847
Electronic ISSN: 1534-3146
DOI
https://doi.org/10.1007/s11908-023-00812-w
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits